OncoMatch/Clinical Trials/NCT06196788
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
Is NCT06196788 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Gemcitabine and Nab paclitaxel for pancreatic cancer.
Treatment: Gemcitabine · Nab paclitaxel — The purpose of this study is to evaluate the efficacy of gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion to Patients with Advanced Pancreatic Cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-tumor chemotherapy
Patients who have received anti-tumor chemotherapy, radiotherapy, or other treatments.
Cannot have received: radiotherapy
Patients who have received anti-tumor chemotherapy, radiotherapy, or other treatments.
Cannot have received: other major anti-cancer treatments
Primary pancreatic cancer without major anti-cancer treatments.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify